Certain chemical entities chosen from compounds of Formula I:and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof are described. Pharmaceutical compositions comprising at least one chemical entity chosen from compounds of Formula I and a pharmaceutically acceptable vehicle are described. Also described are methods for inhibiting α-2,3-sialyltransferase activity in cells, and methods for treating a patient having a disease responsive to inhibition of α-2,3-sialyltransferase activity.
